Stenting and Dilation Devices Market Size, Share & Trends Analysis - Global - 2025-2032 - Includes: Esophageal Stents, Duodenal Stents, Colonic Stents, and 3 more
Description
Global Stenting & Dilation Device Market Report, 2025 Edition
Executive Summary
The global stenting and dilation device market was valued at approximately $689 million in 2025. The market is projected to grow at a compound annual growth rate (CAGR) of 3%, reaching more than $847 million by 2031.
This report covers esophageal stents and dilation balloons, duodenal stents and dilation balloons, and colonic stents and dilation balloons. Biliary and pancreatic stents and dilation balloons are analyzed separately under the endoscopic retrograde cholangiopancreatography (ERCP) market chapter.
The report quantifies units, average selling prices (ASPs), market values, growth rates, and company shares, and it provides a detailed analysis of market drivers and limiters, mergers and acquisitions, and technology trends. It includes historical data from 2021 to 2024 and forecasts to 2031.
The scope reflects how technological innovation, expanding clinical indications, and material advancements continue to shape product adoption and performance across gastrointestinal (GI) procedures worldwide.
Market Overview
Stenting and dilation devices are central to the management of strictures and obstructions within the gastrointestinal tract. These devices are used to restore luminal patency and relieve symptoms in patients with malignant and benign conditions of the esophagus, duodenum, and colon.
In recent years, the market has evolved significantly as physicians adopt less invasive alternatives to surgery. Stenting procedures now represent a primary treatment option in cases where surgical intervention once dominated. The growing preference for endoscopic solutions aligns with the medical community’s broader shift toward shorter hospital stays, lower complication risks, and reduced recovery times.
The transition from bare-metal to fully covered self-expanding metal stents (SEMS) underscores a clear trend toward improved safety and retrievability. Developments in bioabsorbable and drug-eluting stents are expanding the therapeutic landscape, with early clinical evidence showing better patient tolerance and reduced restenosis rates.
Meanwhile, dilation balloons continue to gain traction as an adjunct or standalone therapy for stricture management. Multi-stage balloon systems that enable progressive dilation through a single device are improving procedural efficiency and outcomes, supporting stronger ASPs and contributing to market value growth.
Overall, the global stenting and dilation market reflects the convergence of clinical efficacy, material innovation, and cost-effectiveness, positioning these technologies as key enablers of minimally invasive care.
Market Drivers
Expansion of Uses and Indications
Physician adoption of stents and dilation balloons has expanded beyond traditional oncologic applications into new therapeutic areas, including benign esophageal strictures, bariatric complications, and post-surgical leaks. Clinical studies have demonstrated that duodenal stenting is often less invasive and more cost-effective than surgical alternatives for managing obstructive strictures, supporting its broader use in both palliative and curative settings.
As healthcare systems prioritize value-based outcomes, stenting has become a preferred treatment pathway for cost-sensitive patients and payers. Likewise, the adoption of esophageal dilation balloons continues to rise as awareness grows around reflux-related disorders and the benefits of reinforcing weakened tissue without open surgery.
These trends are expanding procedural volumes globally, particularly in regions where healthcare systems are strengthening endoscopic capabilities.
New Technologies
Innovation is a primary growth driver for the global stenting and dilation market. The introduction of fully covered metal stents has improved removal capability, reduced tissue ingrowth, and lowered complication rates. By 2025, bioabsorbable and drug-eluting stents had moved from pilot studies into commercial availability, with early adopters reporting improved patient outcomes.
Material science continues to advance, with lighter and stronger alloys and polymer coatings enhancing device flexibility and radial force while minimizing migration. These developments are improving procedural success and contributing to better long-term patency rates, fueling sustained market growth.
Multi-Stage Dilation Balloons
Surgeons increasingly prefer multi-stage dilation balloons over single-stage designs because they allow gradual, controlled dilation of strictures. This method has been clinically shown to reduce tissue trauma and perforation risk while improving lumen expansion consistency.
Although multi-stage systems carry higher ASPs than conventional balloons, their superior safety and effectiveness are driving adoption across major markets. As these devices become standard practice, they are expected to elevate overall market value and support the growth of the premium product segment.
Market Limiters
Despite promising growth, several factors continue to constrain broader market expansion.
Cost Pressures and Reimbursement Challenges
Reimbursement structures vary widely across regions, and in some developing markets, coverage for GI stenting procedures remains limited. Hospitals facing budget constraints often prioritize reusable or lower-cost options, reducing ASP growth potential.
Clinical Training and Access to Equipment
In lower-resource regions, access to high-quality endoscopy suites and trained personnel remains inconsistent. The learning curve for complex stenting procedures can limit adoption, particularly for emerging technologies like bioabsorbable stents.
Device Migration and Complications
While material improvements have reduced complications, stent migration and occlusion remain clinical concerns. These issues can lead to repeat procedures, increasing total cost of care and influencing product preference toward more established designs.
Overall, market growth depends heavily on training, evidence generation, and reimbursement expansion, particularly in emerging regions.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, and market forecasts
Growth rates, units sold, and average selling prices (ASPs)
Qualitative Coverage
Growth trends, market limiters, and technology advancements
Competitive analysis, mergers and acquisitions
Company profiles and product portfolios
Procedure numbers and technology trends shaping adoption
Time Frame
Base year: 2025
Forecasts: 2025–2032
Historical data: 2022–2024
Data Sources
Primary interviews with gastroenterologists and industry experts, regulatory and hospital procurement data, import and export data, and the iData Research internal database.
Method Note
Market revenues are modeled from units multiplied by ASP, validated with procedural data, utilization rates, and replacement assumptions for each stent and balloon category.
Markets Covered and Segmentation
Stenting & Dilation Device Market – Further Segmented Into:
Esophageal Stent
Duodenal Stent
Colonic Stent
Esophageal Dilation Balloon
Duodenal Dilation Balloon
Colonic Dilation Balloon
Competitive Analysis
The global stenting and dilation device market is moderately concentrated, with a few multinational firms accounting for the majority of global revenue.
Boston Scientific led the market in 2025, holding approximately 50% of total market share. The company’s broad endoscopic accessories portfolio enables hospitals to source multiple device categories from a single vendor, reinforcing brand loyalty and simplifying procurement. Boston Scientific’s stent technologies are widely recognized for their clinical reliability and global distribution reach.
Cook Medical ranked second in 2025, maintaining a strong presence in dilation balloons and specialized esophageal applications. The company offers three esophageal balloon lines, including Quantum TTC® dilation balloons, designed specifically for treating achalasia. Through its focus on this clinical niche, Cook Medical supplies a large proportion of balloons used for esophageal motility disorders worldwide.
Olympus Corporation held the third-largest position, strengthened by its acquisition of Taewoong Medical Co., Ltd., a South Korean manufacturer of GI metallic stents. This acquisition expanded Olympus’s product range and geographic reach, especially across Europe. The company’s Niti-S™ and COMVI™ product lines include fully and partially covered stents for esophageal, duodenal, and colonic use. Olympus’s competitive pricing and partnerships with national distributors across 25 countries make its portfolio appealing to cost-conscious healthcare systems.
Other participants include regional manufacturers active in limited geographies or product types. The concentrated nature of the market encourages continued investment in quality, evidence generation, and product differentiation, while raising the entry barrier for new competitors.
Technology and Practice Trends
Fully covered and drug-eluting stents are replacing older bare-metal designs due to improved removability and reduced tissue ingrowth.
Bioabsorbable stent technologies are in early adoption stages, showing promise for temporary indications.
Multi-stage dilation balloons are becoming standard for benign strictures due to superior safety outcomes.
Improved delivery systems now allow more precise placement, reducing procedural time and fluoroscopy exposure.
Material innovation, including hybrid polymer-metal frameworks, is enhancing radial force while minimizing patient discomfort.
Clinical focus is shifting toward evidence-based selection of stent type and coverage, supported by international guidelines that standardize practice patterns.
Geography
This edition provides global coverage, including detailed breakdowns for North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Why This Report
Where are the largest and fastest-growing opportunities within the global stenting and dilation device market, and which categories are expected to gain share through 2031?
How are technological innovations, including bioabsorbable materials and drug-eluting designs, reshaping product performance and clinical decision-making?
What are the economic and procedural trends influencing adoption across regions, and how do reimbursement models affect market potential?
How are training access, material advancements, and patient safety outcomes influencing hospital purchasing decisions?
Which product types and manufacturers are most strongly positioned to benefit from the ongoing shift toward minimally invasive GI therapies?
How can suppliers leverage multi-stage balloon innovations and next-generation stent designs to strengthen their market position and pricing strategy?
The Global Stenting & Dilation Device Market Report from iData Research answers these questions with procedure-aware modeling, company share analysis, and price benchmarking. Use it to quantify demand, plan portfolio strategy, guide pricing decisions, and identify the next phase of global growth opportunities.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows
Executive Summary
The global stenting and dilation device market was valued at approximately $689 million in 2025. The market is projected to grow at a compound annual growth rate (CAGR) of 3%, reaching more than $847 million by 2031.
This report covers esophageal stents and dilation balloons, duodenal stents and dilation balloons, and colonic stents and dilation balloons. Biliary and pancreatic stents and dilation balloons are analyzed separately under the endoscopic retrograde cholangiopancreatography (ERCP) market chapter.
The report quantifies units, average selling prices (ASPs), market values, growth rates, and company shares, and it provides a detailed analysis of market drivers and limiters, mergers and acquisitions, and technology trends. It includes historical data from 2021 to 2024 and forecasts to 2031.
The scope reflects how technological innovation, expanding clinical indications, and material advancements continue to shape product adoption and performance across gastrointestinal (GI) procedures worldwide.
Market Overview
Stenting and dilation devices are central to the management of strictures and obstructions within the gastrointestinal tract. These devices are used to restore luminal patency and relieve symptoms in patients with malignant and benign conditions of the esophagus, duodenum, and colon.
In recent years, the market has evolved significantly as physicians adopt less invasive alternatives to surgery. Stenting procedures now represent a primary treatment option in cases where surgical intervention once dominated. The growing preference for endoscopic solutions aligns with the medical community’s broader shift toward shorter hospital stays, lower complication risks, and reduced recovery times.
The transition from bare-metal to fully covered self-expanding metal stents (SEMS) underscores a clear trend toward improved safety and retrievability. Developments in bioabsorbable and drug-eluting stents are expanding the therapeutic landscape, with early clinical evidence showing better patient tolerance and reduced restenosis rates.
Meanwhile, dilation balloons continue to gain traction as an adjunct or standalone therapy for stricture management. Multi-stage balloon systems that enable progressive dilation through a single device are improving procedural efficiency and outcomes, supporting stronger ASPs and contributing to market value growth.
Overall, the global stenting and dilation market reflects the convergence of clinical efficacy, material innovation, and cost-effectiveness, positioning these technologies as key enablers of minimally invasive care.
Market Drivers
Expansion of Uses and Indications
Physician adoption of stents and dilation balloons has expanded beyond traditional oncologic applications into new therapeutic areas, including benign esophageal strictures, bariatric complications, and post-surgical leaks. Clinical studies have demonstrated that duodenal stenting is often less invasive and more cost-effective than surgical alternatives for managing obstructive strictures, supporting its broader use in both palliative and curative settings.
As healthcare systems prioritize value-based outcomes, stenting has become a preferred treatment pathway for cost-sensitive patients and payers. Likewise, the adoption of esophageal dilation balloons continues to rise as awareness grows around reflux-related disorders and the benefits of reinforcing weakened tissue without open surgery.
These trends are expanding procedural volumes globally, particularly in regions where healthcare systems are strengthening endoscopic capabilities.
New Technologies
Innovation is a primary growth driver for the global stenting and dilation market. The introduction of fully covered metal stents has improved removal capability, reduced tissue ingrowth, and lowered complication rates. By 2025, bioabsorbable and drug-eluting stents had moved from pilot studies into commercial availability, with early adopters reporting improved patient outcomes.
Material science continues to advance, with lighter and stronger alloys and polymer coatings enhancing device flexibility and radial force while minimizing migration. These developments are improving procedural success and contributing to better long-term patency rates, fueling sustained market growth.
Multi-Stage Dilation Balloons
Surgeons increasingly prefer multi-stage dilation balloons over single-stage designs because they allow gradual, controlled dilation of strictures. This method has been clinically shown to reduce tissue trauma and perforation risk while improving lumen expansion consistency.
Although multi-stage systems carry higher ASPs than conventional balloons, their superior safety and effectiveness are driving adoption across major markets. As these devices become standard practice, they are expected to elevate overall market value and support the growth of the premium product segment.
Market Limiters
Despite promising growth, several factors continue to constrain broader market expansion.
Cost Pressures and Reimbursement Challenges
Reimbursement structures vary widely across regions, and in some developing markets, coverage for GI stenting procedures remains limited. Hospitals facing budget constraints often prioritize reusable or lower-cost options, reducing ASP growth potential.
Clinical Training and Access to Equipment
In lower-resource regions, access to high-quality endoscopy suites and trained personnel remains inconsistent. The learning curve for complex stenting procedures can limit adoption, particularly for emerging technologies like bioabsorbable stents.
Device Migration and Complications
While material improvements have reduced complications, stent migration and occlusion remain clinical concerns. These issues can lead to repeat procedures, increasing total cost of care and influencing product preference toward more established designs.
Overall, market growth depends heavily on training, evidence generation, and reimbursement expansion, particularly in emerging regions.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, and market forecasts
Growth rates, units sold, and average selling prices (ASPs)
Qualitative Coverage
Growth trends, market limiters, and technology advancements
Competitive analysis, mergers and acquisitions
Company profiles and product portfolios
Procedure numbers and technology trends shaping adoption
Time Frame
Base year: 2025
Forecasts: 2025–2032
Historical data: 2022–2024
Data Sources
Primary interviews with gastroenterologists and industry experts, regulatory and hospital procurement data, import and export data, and the iData Research internal database.
Method Note
Market revenues are modeled from units multiplied by ASP, validated with procedural data, utilization rates, and replacement assumptions for each stent and balloon category.
Markets Covered and Segmentation
Stenting & Dilation Device Market – Further Segmented Into:
Esophageal Stent
Duodenal Stent
Colonic Stent
Esophageal Dilation Balloon
Duodenal Dilation Balloon
Colonic Dilation Balloon
Competitive Analysis
The global stenting and dilation device market is moderately concentrated, with a few multinational firms accounting for the majority of global revenue.
Boston Scientific led the market in 2025, holding approximately 50% of total market share. The company’s broad endoscopic accessories portfolio enables hospitals to source multiple device categories from a single vendor, reinforcing brand loyalty and simplifying procurement. Boston Scientific’s stent technologies are widely recognized for their clinical reliability and global distribution reach.
Cook Medical ranked second in 2025, maintaining a strong presence in dilation balloons and specialized esophageal applications. The company offers three esophageal balloon lines, including Quantum TTC® dilation balloons, designed specifically for treating achalasia. Through its focus on this clinical niche, Cook Medical supplies a large proportion of balloons used for esophageal motility disorders worldwide.
Olympus Corporation held the third-largest position, strengthened by its acquisition of Taewoong Medical Co., Ltd., a South Korean manufacturer of GI metallic stents. This acquisition expanded Olympus’s product range and geographic reach, especially across Europe. The company’s Niti-S™ and COMVI™ product lines include fully and partially covered stents for esophageal, duodenal, and colonic use. Olympus’s competitive pricing and partnerships with national distributors across 25 countries make its portfolio appealing to cost-conscious healthcare systems.
Other participants include regional manufacturers active in limited geographies or product types. The concentrated nature of the market encourages continued investment in quality, evidence generation, and product differentiation, while raising the entry barrier for new competitors.
Technology and Practice Trends
Fully covered and drug-eluting stents are replacing older bare-metal designs due to improved removability and reduced tissue ingrowth.
Bioabsorbable stent technologies are in early adoption stages, showing promise for temporary indications.
Multi-stage dilation balloons are becoming standard for benign strictures due to superior safety outcomes.
Improved delivery systems now allow more precise placement, reducing procedural time and fluoroscopy exposure.
Material innovation, including hybrid polymer-metal frameworks, is enhancing radial force while minimizing patient discomfort.
Clinical focus is shifting toward evidence-based selection of stent type and coverage, supported by international guidelines that standardize practice patterns.
Geography
This edition provides global coverage, including detailed breakdowns for North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Why This Report
Where are the largest and fastest-growing opportunities within the global stenting and dilation device market, and which categories are expected to gain share through 2031?
How are technological innovations, including bioabsorbable materials and drug-eluting designs, reshaping product performance and clinical decision-making?
What are the economic and procedural trends influencing adoption across regions, and how do reimbursement models affect market potential?
How are training access, material advancements, and patient safety outcomes influencing hospital purchasing decisions?
Which product types and manufacturers are most strongly positioned to benefit from the ongoing shift toward minimally invasive GI therapies?
How can suppliers leverage multi-stage balloon innovations and next-generation stent designs to strengthen their market position and pricing strategy?
The Global Stenting & Dilation Device Market Report from iData Research answers these questions with procedure-aware modeling, company share analysis, and price benchmarking. Use it to quantify demand, plan portfolio strategy, guide pricing decisions, and identify the next phase of global growth opportunities.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows
Table of Contents
197 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
